Healthcare provider profile · identity verified

Marc Josef Conte-Russian, D.O.

Internal Medicine · WINFIELD, IL · NPI 1427378413

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	466	135
Amlodipine Besylate	Amlodipine Besylate	256	73
Lisinopril	Lisinopril	215	66
Levothyroxine Sodium	Levothyroxine Sodium	182	57
Omeprazole	Omeprazole	161	43
Rosuvastatin Calcium	Rosuvastatin Calcium	144	51
Losartan Potassium	Losartan Potassium	135	38
Tamsulosin Hcl	Tamsulosin Hcl	124	37
Metoprolol Succinate	Metoprolol Succinate	117	32
Simvastatin	Simvastatin	110	33
Metformin Hcl Er	Metformin Hcl	109	31
Allopurinol	Allopurinol	85	26
Metformin Hcl	Metformin Hcl	85	29
Hydrochlorothiazide	Hydrochlorothiazide	81	28
Eliquis	Apixaban	79	19
Pantoprazole Sodium	Pantoprazole Sodium	74	20
Alendronate Sodium	Alendronate Sodium	64	24
Gabapentin	Gabapentin	64	20
Potassium Chloride	Potassium Chloride	63	14
Furosemide	Furosemide	61	18
Spironolactone	Spironolactone	44	14
Ezetimibe	Ezetimibe	43	18
Xarelto	Rivaroxaban	43	suppressed
Fluticasone Propionate	Fluticasone Propionate	42	29
Alprazolam	Alprazolam	37	12
Atenolol	Atenolol	36	suppressed
Ozempic	Semaglutide	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	36	15
Glipizide Er	Glipizide	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	32	12
Sertraline Hcl	Sertraline Hcl	31	suppressed
Cephalexin	Cephalexin	29	21
Methylprednisolone	Methylprednisolone	29	28
Finasteride	Finasteride	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Trazodone Hcl	Trazodone Hcl	26	suppressed
Benazepril Hcl	Benazepril Hcl	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	11
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Prednisone	Prednisone	21	14
Albuterol Sulfate Hfa	Albuterol Sulfate	20	11
Bupropion Xl	Bupropion Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Midodrine Hcl	Midodrine Hcl	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	12
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Famotidine	Famotidine	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Azithromycin	Azithromycin	11	11
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error